<DOC>
	<DOC>NCT01440179</DOC>
	<brief_summary>Primary Objective: Participants achieving an Objective Response Rate Secondary Objectives: - Response duration - Progression Free Survival - Minimal residual disease - Safety - Pharmacokinetics</brief_summary>
	<brief_title>SAR3419 in Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>The duration of the study for an individual patient will include: - The screening period = up to 4 weeks prior to the first administration of SAR3419. - The treatment period: - Induction period = 4 to 8 weeks - Maintenance = up to a total maintenance treatment of 6 months - A safety follow-up period of 42 days after the last dose. - Any patient who discontinues the study treatment without disease progression will be followed every 2 months until disease progression, initiation of a new anti-cancer therapy, death or end-of-study date, whatever comes first.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Inclusion criteria: Previously treated Acute Lymphoblastic Leukemia of B cell origin (including Burkitt's lymphoma) in relapse or primary refractory. Patients in first relapse will be eligible regardless of the first remission duration. No more than 3 prior salvage therapies. Philadelphia positive patients failing treatment with imatinib mesylate are accepted. CD19 positive patients. Exclusion criteria: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>